| Budget Amount *help |
¥18,850,000 (Direct Cost: ¥14,500,000、Indirect Cost: ¥4,350,000)
Fiscal Year 2010: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2009: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2008: ¥8,970,000 (Direct Cost: ¥6,900,000、Indirect Cost: ¥2,070,000)
|
|---|
| Research Abstract |
Toward developing a therapy for the polyglutamine (polyQ) neurodegenerative diseases targeting β-sheet conformers and oligomers of the expanded polyQ protein,1)we showed the modest therapeutic effects of PTD-QBP1 on a mouse model of the polyQ diseases, and determined essential residues within QBP1 for its activity.2)We identified 9 polyQ aggregation inhibitors which exhibit therapeutic effects on a Drosophila model of the polyQ diseases.3)We demonstrated the therapeutic effects of 17-AAG, a chaperone-inducing compound, on polyQ disease Drosophila models.
|
